Skip to content
Home/Companies/Biotech/Brainvectis

Brainvectis

Biotech·France·Exited 2020·Held 5yr
Entry
2015
Hold
5yr
Exit
2020

Who owns Brainvectis?

Brainvectis is a French Biotech company, now owned by Asklepios BioPharmaceutical, which acquired it in 2020 from Erganeo.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Erganeo
Investor
Erganeo
Erganeo · 2012 · VC

Key facts

HQFrance
SectorBiotech
Exit Type
Trade Sale
Buyer
Asklepios BioPharmaceutical
Exit Year
2020

More from Erganeo

Other portfolio companies in the same fund.

Greennovation
Active
France· 2025
Lafame
Active
France· 2025
PegmaTiss BioTech
Active
HealthcareFrance· 2023
Izonics
Active
IndustrialsFrance· 2022
Persea
Active
BiotechFrance· 2022
AbilyCare
Active
HealthTechFrance· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Brainvectis?

Brainvectis is now owned by Asklepios BioPharmaceutical, which acquired it in 2020 from Erganeo.

When did Asklepios BioPharmaceutical acquire Brainvectis?

Asklepios BioPharmaceutical acquired Brainvectis in 2020, buying from Erganeo.

Who did Brainvectis sell to?

Erganeo sold Brainvectis to Asklepios BioPharmaceutical in 2020 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue